Titlebook: Cardiovascular Outcomes Research; A Clinician’s Guide Kevin C. Maki,Don P. Wilson Book 2024 The Editor(s) (if applicable) and The Author(s

機(jī)會

書目名稱Cardiovascular Outcomes Research影響因子(影響力)




書目名稱Cardiovascular Outcomes Research影響因子(影響力)學(xué)科排名




書目名稱Cardiovascular Outcomes Research網(wǎng)絡(luò)公開度




書目名稱Cardiovascular Outcomes Research網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Cardiovascular Outcomes Research被引頻次




書目名稱Cardiovascular Outcomes Research被引頻次學(xué)科排名




書目名稱Cardiovascular Outcomes Research年度引用




書目名稱Cardiovascular Outcomes Research年度引用學(xué)科排名




書目名稱Cardiovascular Outcomes Research讀者反饋




書目名稱Cardiovascular Outcomes Research讀者反饋學(xué)科排名

易于出錯

2196-8969 scular Outcomes Research.?is a must-have resource for physicians and other clinicians, residents, fellows, and medical students in cardiology, endocrinology, primary care, and health promotion and disease preve978-3-031-54962-5978-3-031-54960-1Series ISSN 2196-8969 Series E-ISSN 2196-8977

jealousy

Pharmaceutical Development and Approval in the United States of Agents to Influence Cardiovascular H undertaking a Phase 3 trial to demonstrate efficacy for reducing the risk of clinical events, such as a trial to demonstrate a reduced risk of major adverse cardiovascular events (MACE), referred to as a cardiovascular outcomes trial (CVOT). Particular attention toward assessing the cardiovascular

有罪

Biomarkers and Imaging Modalities to Detect Subclinical Atherosclerotic Cardiovascular Diseasevasive imaging tests better predicts major adverse cardiovascular events, especially in populations where the risk estimation may not be applicable (i.e., familial hypercholesterolemia), or where they may underestimate risk in some populations or overestimate risk in populations with protective risk

BRIEF

An Overview of the Guideline Development Process for Atherosclerotic Cardiovascular Disease Risk Reded to present recommendations; this includes a table of the recommendations, synopsis, supporting text, and flow diagrams or additional tables for each “chunk” of information. The process of guideline development depends on the philosophy and instructional approach that is most representative of the

使服水土

Lifestyle Interventions and Atherosclerotic Cardiovascular Disease Outcomesatty acids and replace with unsaturated fatty acids; (3) limit intakes of foods and beverages with added sugars; (4) abstinence of alcohol for those who do not currently drink and limit alcohol intake to ≤1 drink/day for men and women who choose to drink; (5) participate in sufficient quantities and

使服水土

Inflammation and Cardiovascular Outcomes targets of inflammation aimed at reducing cardiovascular risk. The chapter also discusses the evidence behind anti-inflammatory therapies that are currently being studied in primary and secondary ASCVD prevention settings. Targeting inflammation has the potential to develop novel avenues to reduce

Anticlimax

疲憊的老馬

劇毒

Pharmacotherapy for Obesity: Recent Evolution and Implications for Cardiovascular Risk Reductionbesity is lifestyle intervention for weight loss, combined with the treatment of obesity-related cardiometabolic risk factors individually. The use of medications to treat obesity is relatively rare. In part, this reflects concerns about long-term safety and weight loss effectiveness, possible provi